BERLIN--(BUSINESS WIRE)-- Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results